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DOI 10.1186/s13024-015-0049-0RESEARCH ARTICLE Open AccessRegion-specific dendritic simplification
induced by Aβ, mediated by tau via
dysregulation of microtubule dynamics: a
mechanistic distinct event from other
neurodegenerative processes
Nataliya Golovyashkina1, Lorène Penazzi1, Carlo Ballatore2,3, Amos B. Smith III2, Lidia Bakota1 and Roland Brandt1*Abstract
Background: Dendritic simplification, a key feature of the neurodegenerative triad of Alzheimer’s disease (AD) in
addition to spine changes and neuron loss, occurs in a region-specific manner. However, it is unknown how
changes in dendritic complexity are mediated and how they relate to spine changes and neuron loss.
Results: To investigate the mechanisms of dendritic simplification in an authentic CNS environment we employed
an ex vivo model, based on targeted expression of enhanced green fluorescent protein (EGFP)-tagged constructs in
organotypic hippocampal slices of mice. Algorithm-based 3D reconstruction of whole neuron morphology in
different hippocampal regions was performed on slices from APPSDL-transgenic and control animals. We
demonstrate that induction of dendritic simplification requires the combined action of amyloid beta (Aβ) and
human tau. Simplification is restricted to principal neurons of the CA1 region, recapitulating the region specificity in
AD patients, and occurs at sites of Schaffer collateral input. We report that γ-secretase inhibition and treatment with
the NMDA-receptor antagonist, CPP, counteract dendritic simplification. The microtubule-stabilizing drug epothilone
D (EpoD) induces simplification in control cultures per se. Similar morphological changes were induced by a
phosphoblocking tau construct, which also increases microtubule stability. In fact, low nanomolar concentrations of
naturally secreted Aβ decreased phosphorylation at S262 in a cellular model, a site which is known to directly
modulate tau-microtubule interactions.
Conclusions: The data provide evidence that dendritic simplification is mechanistically distinct from other
neurodegenerative events and involves microtubule stabilization by dendritic tau, which becomes
dephosphorylated at certain sites. They imply that treatments leading to an overall decrease of tau phosphorylation
might have a negative impact on neuronal connectivity.
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Alzheimer’s disease (AD) is characterized by the neuro-
degenerative triad of spine changes, dendritic simplifica-
tion and neuron loss [1]. The pathologic changes are
accompanied by the formation of extracellular plaques,
composed of Aβ peptides, and intracellular neurofibril-
lary tangles containing tau in a hyperphosphorylated
state [2, 3]. While the development of spine changes and
neuron loss has been addressed in various animal and
culture models [4–7], much less is known about how
changes in dendritic complexity are mediated. Spires
et al. [7] reported dendritic changes in plaque developing
mice and Wu et al. [8] provided evidence that activation
of the calcium-dependent phosphatase calcineurin is in-
volved in Aβ-induced dendritic simplification, however
it remains unclear how these changes are mediated. The
lack of knowledge is noteworthy since dendritic simplifi-
cation, which has long been recognized in AD, is likely
to contribute to brain malfunction to a major extent and
is considered to be a forerunner to neuronal loss [9].
A number of careful morphological studies of human
brain material have established that alterations in den-
dritic arbor are regionally specific in AD [10]. In the
hippocampus, dendritic extent is largely reduced in CA1
pyramidal neurons [11], while no changes were observed
in CA3 neurons [12, 13]. The differences appear not to
be due to postsynaptic dendritic regression since no ex-
cess loss of CA3 pyramidal neurons was observed [14].
Loss of spines is more widespread [15], suggesting that
dendritic simplification develops independent from spine
changes and neuronal loss. How changes in neuronal
morphology develop during disease is however largely
unknown.
Neuronal morphology is highly dependent on the
organization of the cytoskeleton with microtubules play-
ing an important role in regulating dendritic arborization
[16]. The microtubule-associated tau proteins, known to
modulate microtubule dynamics in neurons [17], are
present and functionally active to a major extent in
dendrites [18, 19] and may also be involved in dendritic
remodeling during health and disease [20]. However,
whether Aβ and tau are involved in dendritic simplifica-
tion and whether they functionally interact to execute
these changes is unknown.
To scrutinize the mechanisms of dendritic simplifica-
tion in an authentic CNS environment, we employed a
previously established ex vivo model based on targeted
expression of EGFP-tagged constructs in organotypic
hippocampal slices [5]. We demonstrate that dendritic
simplification is restricted to principal neurons of the
CA1 region, and is induced by Aβ, mediated by tau
through NMDA receptor activation. We provide evi-
dence that dendritic simplification involves dysregula-
tion of microtubule dynamics by dendritic tau, whichbecomes dephosphorylated at certain sites, and is mech-
anistically distinct from spine changes and neuron loss.
Results
Induction of dendritic simplification requires the action of
human tau on an APPSDL transgenic background
We employed an ex vivo model of AD using organotypic
hippocampal slice cultures from APPSDL transgenic mice
in combination with Sindbis virus-mediated expression
of EGFP-tagged constructs. We demonstrated previously
that this approach permits analysis of cell death and
synaptic changes with respect to the functional inter-
action between Aβ and tau pathology [5]; here we have
extended the approach to determine region-specific
changes in dendritic morphology. Virus infections were
performed at 12 days in vitro (DIV) and slices were ana-
lyzed 3 days later (Fig. 1a). At these conditions efficient
neuronal expression of EGFP with low toxicity was ob-
tained [21]. We have also shown previously that the ex-
pression levels of different EGFP-tau constructs are
similar [5, 21]. Virus titer was adjusted to achieve low
infection rate in CA1, CA3 and DG, which permitted 3D
imaging of single neurons by high-resolution cLSM with
minimal overlap of dendritic arbors (Fig. 1b). Image tile
stacks were stitched into single neurons and the morph-
ology of whole neurons was reconstructed in 3D by au-
tomated digitalization (Fig. 1c) [22]. The detection gain
was adjusted to capture the full arbor, including smaller
secondary and tertiary dendrites, irrespective of the
EGFP-construct used. Comparing neuronal morphology
after virus infection in slices prepared from APPSDL
transgenic mice versus B6 controls permitted determin-
ation of the effect of the APP transgene on dendritic
morphology in the apical (red) and basal (blue) arbor in
principal neurons from the different hippocampal re-
gions (Fig. 1d).
For a quantitative assessment of potential changes in
dendritic arborization, we determined the total path
length and the number of branching points in principal
neurons from CA1, CA3 and DG. Expression of EGFP
alone on APPSDL transgenic background induced only
slight dendritic simplification, which did not reach sig-
nificance. In contrast, we observed that EGFP-htau ex-
pression on APPSDL transgenic background induced
pronounced and significant dendritic simplification in
CA1 neurons as indicated by a reduction of total path
length and number of branching points by 38 % and
30 %, respectively (Fig. 2a, left). No change was seen in
CA3 pyramidal neurons and granule cells of the DG
(Fig. 2a, middle and right). Human tau expression on
non-transgenic background did not induce morpho-
logical changes, indicating that dendritic simplification
in the CA1 region requires the combination of human
tau and APPSDL transgenic background.
Fig. 1 Analysis of dendritic simplification in an ex vivo model of Alzheimer’s disease. a Outline of the experimental approach. 400 μm-thick
hippocampal sections from APPSDL transgenic or non-transgenic mice were cultured using the membrane interface technique. Sindbis virus
infection to express EGFP-tagged constructs was performed at day 12 in vitro (DIV). Slices were fixed three days later as indicated on the time line.
b Fluorescence micrograph of a whole slice showing infected and EGFP-expressing neurons in DG, CA1 and CA3 regions. Scale bar, 150 μm.
c High resolution fluorescence micrograph of a CA1 pyramidal neuron after semi-automated stitching (left) and 3D reconstruction (right). The
apical part of the dendritic tree is indicated in red, the basal part in blue and the axon in turquoise. Scale bar, 50 μm. d 3D reconstructions of
representative CA1, CA3 and DG neurons from APPSDL transgenic and non-transgenic (B6) mice after expression of EGFP-htau
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collateral input in CA1 neurons
CA1 pyramidal neurons receive different inputs in spe-
cific subregions of the dendritic tree (Fig. 2b). To deter-
mine subregional differences in the induction of
dendritic simplification, 3D Sholl analysis [23] was per-
formed on basal and apical branches to quantitate
changes in the intersection frequency of dendrites as a
function of the distance from the cell body (Fig. 2c, left).
On the APP transgenic background we observed a re-
duction of dendritic complexity in the entire basal part
of the tree (Fig. 2c, right). In contrast, in the apical part,
dendritic simplification was induced specifically in two
segments of the tree. Responsive segments were local-
ized at ~15-25 % and ~60-70 % of total apical length
and correlated with regions, where most input from
Schaffer collaterals occurs (see Fig. 2b).
γ-Secretase inhibition and treatment with NMDA receptor
inhibitors counteract dendritic simplification
Dendritic simplification could be induced by the pres-
ence of mutated APP or might require the generation
of Aβ through γ- and β-secretase mediated cleavage
of APPSDL. To distinguish between these possibilities,
we pretreated the culture with the non-transition state
γ-secretase inhibitor DAPT in order to reduce Aβ gen-
eration [24]. Treatment with DAPT was started one
day before infection with EGFP-htau expressing virus(Fig. 3a, top). DAPT reduced the negative effect of tau and
APP on dendritic complexity in CA1 neurons as judged
by a significant increase in total path length compared to
untreated cultures of the same genotype (Fig. 3a, bottom).
Sholl analysis of CA1 neurons revealed that dendritic sim-
plification was completely abolished in basal dendrites
and reduced in apical segments (Fig. 3b). The data indi-
cate that dendritic simplification is induced by Aβ rather
than mutated APP.
It has previously been shown that Aβ acts via NMDA
receptor (NMDAR) activation to induce spine changes
and neuron loss [5, 25, 26]. To test whether NMDAR ac-
tivation is also involved in mediating dendritic simplifi-
cation, we added the competitive NMDAR antagonist
CPP [27] to the cultures one day before infection with
EGFP-htau expressing virus (Fig. 4a, top). CPP also abol-
ished the negative effect of tau and Aβ on dendritic
complexity in CA1 neurons similar to DAPT (Fig. 4a,
bottom, and b), demonstrating that dendritic simplifica-
tion is mediated by NMDAR activation. It should also be
noted that both drugs induced some dendritic simplifica-
tion in CA3 neurons, which might indicate sensitivity of
the CA3 neurons to the drugs themselves.
The microtubule-stabilizing drug EpoD induces dendritic
simplification in control cultures
Data from this study could suggest that Aβ induces
microtubule destabilization in a tau-dependent manner,
Fig. 2 Effect of tau and APP on dendritic morphology of principal hippocampal neurons. a Quantitative analysis of dendritic complexity as
determined from total path length (top) and number of branching points (bottom). Expression of EGFP-htau induces dendritic simplification in
CA1 neurons from APPSDL transgenic mice. b Schematic representation showing the major connectivity in different layers of the hippocampus.
Gray boxes indicate sites of Schaffer collateral input in apical dendrites of CA1 neurons. c 3D Sholl analysis of the basal and apical dendritic tree
in CA1 neurons. A schematic representation illustrating the procedure to determine dendritic intersections is shown left. Significant changes occur
at two segments in the apical dendrite, which are indicated by gray boxes corresponding to the Schaffer collateral input as shown in (b). Statistical
evaluation was performed using two-tailed, unpaired Student’s t test for comparison of the two genotypes in (a) and (c). Values are shown as mean
and s.e.m. *, p < 0.05, **, p < 0.01, ***, p < 0.001. See Table 1 for details on the statistics
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true, one would expect that microtubule-stabilizing
drugs would prevent dendritic simplification. To test this
hypothesis we treated the cultures prior to infection with
the microtubule-stabilizing drug epothilone D (EpoD), a
brain-penetrant small molecule potential therapeutic
candidate for AD [28, 29]. Epothilones may have neuro-
protective activity; however dose-dependent neurotoxic
effects have also been reported [30]. In pilot experiments
we observed loss of neurons in control cultures at con-
centrations of 1 and 5 nM of EpoD indicating some tox-
icity for the cells. The number of neurons was not
affected at 0.2 nM EpoD, a concentration where still in-
duction of microtubule polymerization was observed in
model neurons (data not shown). Thus this concentra-
tion was subsequently used for the experiments. Surpris-
ingly, EpoD induced dendritic simplification in control
cultures as indicated by significantly decreased total path
length and branching compared to the respective un-
treated cultures (Fig. 5a, Table 2). No obvious differences
in the dendritic morphology between htau-expressingAPP-transgenic and control cultures were observed,
which was – except some simplification in basal den-
drites – confirmed by Sholl analysis (Fig. 5b, c).
Expression of phosphoblocking tau induces dendritic
simplification per se and increases microtubule stability
Since microtubule stabilization did not have any effect
in Aβ-producing cultures, we explored whether tau
phosphorylation, which is known to affect microtubule
dynamics, is at all involved in mediating dendritic sim-
plification. We employed a phosphoblocking (Ala htau)
and a phosphomimicking (PHP htau) construct in which
10 AD-relevant sites were modified to alanine to pre-
vent, or to glutamate to simulate, phosphorylation at
these residues (Fig. 6a, top) [31]. Surprisingly, expression
of Ala htau induced dendritic simplification per se
whereas the phosphomimicking PHP htau did not in-
duce morphological changes (Fig. 6a, bottom, Table 1).
This is in sharp contrast to the previous observation that
PHP tau is the active species to induce cell death, and
importantly indicates that the development of dendritic
Fig. 3 Effect of γ-secretase inhibition on dendritic simplification. a Total path length and number of branching points of CA1 and CA3 neurons in
the presence of the γ-secretase inhibitor DAPT. Schematic representation of the time line of the respective experiment is shown on top. DAPT
reduces simplification in CA1 neurons. b Sholl analysis of basal and apical parts of the dendritic tree in CA1 neurons after DAPT treatment. DAPT
completely abolishes simplification of APPSDL transgenic cultures in the basal part and reduces simplification in the apical part of the dendritic
tree. (+) indicates significant increase, (#,##) significant decrease compared to the respective condition without the drug. Statistical evaluation was
performed using one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons (a) and Student’s t test for comparison of the two
genotypes (b). Values are shown as mean and s.e.m. *(#)(+), p < 0.05, (##), p < 0.01. See Table 1 for details on the statistics
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istically distinct. The finding that the effect of Ala htau
expression closely resembles the impact of EpoD-
treatment could suggest that Ala htau induces dendritic
simplification by hyperstabilizing dendritic microtubules.
To test this hypothesis, we determined the influence of
wt htau, Ala htau and PHP htau expression on micro-
tubule stability by determining the ratio of acetylated to
total tubulin, since tubulin acetylation is considered to
be a marker for microtubule stability [32]. Expression of
Ala htau induced a significantly increased ratio of acety-
lated to total tubulin compared to wt htau or PHP htau
expressing cultures (Fig. 6b). This indicates that non-phosphorylatable htau induces dendritic simplification
due to the inherent activity to promote microtubule
stabilization. It should however be noted that Ala htau
expression prevented dendritic simplification in CA1
neurons from APPSDL transgenic animals (Fig. 6a, bot-
tom), which might indicate that it counteracts Aβ-
induced microtubule destabilization in these neurons.
Generally, higher Aβ concentrations are considered to
increase rather than decrease tau phosphorylation, but
the effect of low concentrations of secreted Aβ on the
phosphorylation of human tau is less clear. A previous
study using a coculture system has shown that secreted
Aβ induces an increased phosphorylation at the AT8
Fig. 4 Effect of the NMDA receptor antagonist CPP on dendritic simplification. a Total path length and number of branching points of CA1 and
CA3 neurons in the presence of the NMDAR antagonist CPP. Schematic representation of the time line of the respective experiment is shown on
top. CPP reduces simplification in CA1 neurons. b Sholl analysis of basal and apical parts of the dendritic tree in CA1 neurons after CPP treatment.
CPP completely abolishes simplification of APPSDL transgenic cultures in the basal part and reduces simplification in the apical part of the
dendritic tree. (+) indicates significant increase, (#) significant decrease compared to the respective condition without the drug. Statistical
evaluation was performed using one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons (a) and Student’s t test for comparison
of the two genotypes (b). Values are shown as mean and s.e.m. *(#)(+), p < 0.05. See Table 1 for details on the statistics
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The concentration of Aβ was comparable with that
found in cerebrospinal fluid of AD patients, probably in
the higher nanomolar range. However, a rough estimate
suggests that the amount of Aβ in the brain of APPSDL
transgenic mice that have been used for preparation of
the organotypic slices is in the low nanomolar range (L.
Bakota, unpublished observation), which reflects more a
presymptomatic scenario. To test the hypothesis that
low nanomolar concentrations of naturally secreted Aβ
cause a change in the phosphorylation pattern of tau
that might lead to increased microtubule stabilization,
we turned to a cellular model, where PAGFP-tagged hu-
man tau is stably expressed in rat PC12 cells (Fig. 6c).
The cells were seeded in a defined density, neuronallydifferentiated with NGF and incubated with a super-
natant of APPSwe-transfected HEK cells. Western blot
analysis showed that 3.5 nM Aβ caused a decreased
phosphorylation at S262, while some other sites such as
T181 and S214 were not affected. Interestingly, S262 is
located in the microtubule-binding region of tau and
phosphorylation of S262 largely abolishes its interaction
with microtubules [34]. Thus, even a small decrease in
S262 phosphorylation could induce tau-dependent
microtubule stabilization thereby promoting dendritic
simplification.
Discussion
The major findings of our current study comprise: (1)
dendritic simplification is induced by Aβ and mediated
Fig. 5 Effect of the microtubule-stabilizing drug EpoD on dendritic simplification. a Total path length and number of branching points of CA1
neurons in the presence of EpoD. Schematic representation of the time line of the experiment is shown on top. EpoD causes dendritic
simplification on a non-transgenic background. b, c 3D reconstructions of representative CA1 neurons (c) and Sholl analysis (b) from APPSDL
transgenic and non-transgenic (B6) mice in the presence of EpoD illustrating similar complexity in the basal (blue) and apical (red) part of the
dendritic tree. (#, ##) indicate significant decrease compared to the respective condition without EpoD. Statistical evaluation was performed using
one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons (a) and Student’s t test for comparison of the two genotypes (b). Values are
shown as mean and s.e.m. *(#), p < 0.05, (##), p < 0.01. See Table 2 for details on the statistics
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restricted manner; (2) dendritic simplification is mech-
anistically distinct from other neurodegenerative events;
and (3) dendritic simplification involves microtubule
stabilization by dendritic tau, which becomes dephos-
phorylated at certain sites.
In contrast to spine changes and neuron loss, the
mechanisms that contribute to dendritic simplification
are much less studied. The pattern of dendritic
arborization crucially determines the final integration
of inputs and information processing. Thus, it is clear
that a reduction of total dendritic path length by
about 40 % as we observed it in principal neurons of
the CA1 region (see Fig. 2a), has a major impact on
synaptic connectivity even if the density of spines
would remain unchanged.
It is well established that neuronal activity and activation
of NMDARs play a key role in the regulation of dendritic
arbor elaboration and dynamics as NMDAR-dependentneurotransmission induces an increased complexity of
dendritic branches [35] and hypofunctional NMDARs lead
to dendritic simplification [36]. This is in agreement with
our observation that Aβ induces dendritic simplification
through NMDARs and that morphological changes occur
at sites of Schaffer collateral input, i.e. at glutamatergic
synapses. Downstream signaling pathways may involve
modulation of dendritic Ca2+-dependent plasticity and
may finally be mediated through regulation of cytoskeletal
dynamics. Previous studies have shown that members of
the Rho family of small GTPases such as RhoA and Cdc42
influence dendritic development, possibly by functionally
linking surface receptor activation to the organization of
the actin cytoskeleton [37]. Very recently it also has been
shown that a RhoA signaling pathway regulates the forma-
tion of Golgi outposts that contribute to dendritic growth
and branch dynamics [38]. Interestingly, the activity level
of RhoA appears also to modify the phosphorylation state
of tau [39]. On the other side, tau belongs to the class of
Fig. 6 Effect of phosphoblocking and phosphomimicking tau on dendritic simplification. a Total path length and number of branching points of
CA1 neurons that express phosphoblocking (Ala htau) or phosphomimicking tau (PHP htau). Schematic representations of the respective
construct are shown on the top. Mutated residues are indicated. Ala htau causes dendritic simplification on a non-transgenic background,
whereas PHP htau behaves neutral. b Ratio of acetylated to total tubulin as a marker for microtubule stabilization. Immunoblots showing staining
against acetylated tubulin and total tubulin (top) and the respective quantitation (bottom). Expression of Ala htau causes stabilization of
microtubules. c Effect of low nanomolar concentrations of naturally secreted Aβ on the phosphorylation of tau in model neurons. A schematic
representation of the experimental approach is shown to the left. Neuronally differentiated PC12 cells expressing PAGFP-tagged human tau are
incubated with a supernatant from Aβ-expressing cells (HEK-SW) or the respective controls (HEK-con). Representative Western blots and
quantification of phosphorylation at selected sites is shown to the right. 3.5 nM Aβ induce dephosphorylation of tau at S262. (+) indicate
significant increase, (#, ##) significant reduction compared to neurons expressing wildtype human tau. Statistical evaluation was performed using
one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons (a) and Student’s t test for comparison of the constructs (b) and the
two genotypes (c). Values are shown as mean and s.e.m. See Table 1 for details on the statistics. For (c), 3–10 Western blot experiments were
evaluated per condition. *(#)(+), p < 0.05, **(##), p < 0.01
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as hubs in cellular protein-protein interaction networks
and are involved in signaling [40]. Thus, it is conceivablethat tau phosphorylation influences various signal trans-
duction mechanisms that are involved in the complex
process of dendritic arborization.
Table 1 Dendritic simplification in an ex vivo model of Alzheimer’s disease. Summary representation of the effect of the expressed construct, the genotype of the mouse and
pharmacological treatments on total path length (A) and number of branching points (B). Statistical evaluation was performed using two-tailed, unpaired Student’s t test for
comparison of the two genotypes under control conditions (untreated), and one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons of drug treatments or
different tau constructs. P values, which represent statistical significance (p≤0.05) are indicated in bold, except when the alpha level of ANOVA was above 0.05
A. Total path length
Construct Condition Region Genotype Mice (n) Cells (n) Mean ± s.e.m
(based on cell
number) in mm
Student’s test
p values (B6 vs. APP)
EGFP untreated CA1 B6 5 9 3.113±0.465 p = 0.775
EGFP untreated CA1 APPSDL 5 5 3.364±0.707
EGFP untreated CA3 B6 7 8 4.490±0.292 p = 0.401
EGFP untreated CA3 APPSDL 5 7 4.187±0.202
EGFP untreated DG B6 6 6 1.223±0.232 p = 0.275
EGFP untreated DG APPSDL 5 7 0.911±0.161
EGFP-htau untreated CA1 B6 4 7 3.996±0.237 p = 0.0003
EGFP-htau untreated CA1 APPSDL 6 8 2.491±0.163
EGFP-htau untreated CA3 B6 5 6 4.344±0.423 p = 0.428
EGFP-htau untreated CA3 APPSDL 5 6 3.920±0.283
EGFP-htau untreated DG B6 5 10 0.813±0.071 p = 0.888
EGFP-htau untreated DG APPSDL 7 17 0.826±0.051
Construct Condition Region Genotype Mice (n) Cells (n) Mean ± s.e.m
(based on cell
number) in mm
One way ANOVA (together with
EGFP-htau untreated, both
genotypes, same region)
p values
(B6 vs. APP)
p values ( vs.
untreated EGFP-
htau same region
and same genotype)
EGFP-htau DAPT CA1 B6 4 6 3.691±0.154 F (3,24) = 14.05 ; p < 0.0001 p = 0.0440 p = 0.2657
EGFP-htau DAPT CA1 APPSDL 4 7 3.122±0.154 p = 0.0182
EGFP-htau DAPT CA3 B6 5 6 3.122±0.258 F (3,22) = 3.634 ; p = 0.0287 p = 0.8981 p = 0.0133
EGFP-htau DAPT CA3 APPSDL 4 8 3.177±0.249 p = 0.0940
EGFP-htau CPP CA1 B6 5 7 3.671±0.289 F (3,25) = 7.781 ; p = 0.0008 p = 0.2469 p = 0.3517
EGFP-htau CPP CA1 APPSDL 6 7 3.265±0.263 p = 0.0279
EGFP-htau CPP CA3 B6 6 6 3.714±0.293 F (3,23) = 0.5765 ; p = 0.6363 p = 0.8658 p = 0.2483
EGFP-htau CPP CA3 APPSDL 7 9 3.797±0.357 p = 0.8023
EGFP-htau EpoD CA1 B6 7 8 3.038±0.288 F (3,27) = 7.040 ; p = 0.0012 p = 0.5142 p = 0.0092
EGFP-htau EpoD CA1 APPSDL 8 8 2.820±0.241 p = 0.3273
EGFP-htau EpoD CA3 B6 7 8 3.603±0.186 F (3,23) = 5.757 ; p = 0.0043 p = 0.0416 p = 0.0527
EGFP-htau EpoD CA3 APPSDL 7 7 2.853±0.126 p = 0.0089
EGFP-Ala htau untreated CA1 B6 5 7 2.797±0.268 F (3,24) = 8.839 ; p = 0.0004 p = 0.1005 p = 0.0011
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Table 1 Dendritic simplification in an ex vivo model of Alzheimer’s disease. Summary representation of the effect of the expressed construct, the genotype of the mouse and
pharmacological treatments on total path length (A) and number of branching points (B). Statistical evaluation was performed using two-tailed, unpaired Student’s t test for
comparison of the two genotypes under control conditions (untreated), and one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons of drug treatments or
different tau constructs. P values, which represent statistical significance (p≤0.05) are indicated in bold, except when the alpha level of ANOVA was above 0.05 (Continued)
EGFP-Ala htau untreated CA1 APPSDL 4 6 3.370±0.249 p = 0.0125
EGFP-Ala htau untreated CA3 B6 5 6 2.912±0.224 F (3,20) = 4.276 ; p = 0.0174 p = 0.8829 p = 0.0076
EGFP-Ala htau untreated CA3 APPSDL 4 6 2.984±0.396 p = 0.0667
EGFP-PHP htau untreated CA1 B6 4 7 3.342±0.298 F (3,24) = 5.250 ; p = 0.0063 p = 0.6532 p = 0.1107
EGFP-PHP htau untreated CA1 APPSDL 4 6 3.155±0.429 p = 0.1091
EGFP-PHP htau untreated CA3 B6 5 6 3.578±0.450 F (3,20) = 2.724 ; p = 0.0714 p = 0.1941 p = 0.1722
EGFP-PHP htau untreated CA3 APPSDL 4 6 2.851±0.352 p = 0.0621
Construct Condition Region Genotype Mice (n) Cells (n) Mean ± s.e.m
(based on cell
number) in mm
One way ANOVA (together with
EGFP untreated, both genotypes,
same region)
p values (B6 vs. APP) p values ( vs.
untreated EGFP
same region and
genotype)
EGFP CPP CA1 B6 6 7 3.597±0.207 F (3,23) = 0.4707 ; p = 0.7056 p = 0.7702 p = 0.4144
EGFP CPP CA1 APPSDL 6 6 3.787±0.334 p = 0.5514
EGFP CPP CA3 B6 5 5 3.603±0.244 F (3,22) = 2.806 ; p = 0.0634 p = 0.7762 p = 0.0473
EGFP CPP CA3 APPSDL 5 6 3.474±0.382 p = 0.0974
EGFP EpoD CA1 B6 6 6 3.110±0.307 F (3,23) = 0.2951 ; p = 0.8285 p = 0.4532 p = 0.9960
EGFP EpoD CA1 APPSDL 7 7 3.591±0.168 p = 0.7353
EGFP EpoD CA3 B6 6 6 2.995±0.268 F (3,23) = 5.693 ; p = 0.0046 p = 0.0438 p = 0.0006
EGFP EpoD CA3 APPSDL 6 6 3.851±0.287 p = 0.3939
B. Number of branching points
Construct Condition Region Genotype Mice (n) Cells (n) Mean ± s.e.m
(based on cell
number)
Student’s t test
p values (B6 vs. APP)
EGFP untreated CA1 B6 5 9 31±4.11 p = 0.571
EGFP untreated CA1 APPSDL 5 5 36±7.22
EGFP untreated CA3 B6 7 8 39±3.83 p = 0.203
EGFP untreated CA3 APPSDL 5 7 33±1.90
EGFP untreated DG B6 6 6 11±2.68 p = 0.261
EGFP untreated DG APPSDL 5 7 7±0.57
EGFP-htau untreated CA1 B6 4 7 36±3.58 p = 0.016
EGFP-htau untreated CA1 APPSDL 6 8 23±3.05
EGFP-htau untreated CA3 B6 5 6 40±3.24 p = 0.185
EGFP-htau untreated CA3 APPSDL 5 6 34±2.24
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Table 1 Dendritic simplification in an ex vivo model of Alzheimer’s disease. Summary representation of the effect of the expressed construct, the genotype of the mouse and
pharmacological treatments on total path length (A) and number of branching points (B). Statistical evaluation was performed using two-tailed, unpaired Student’s t test for
comparison of the two genotypes under control conditions (untreated), and one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons of drug treatments or
different tau constructs. P values, which represent statistical significance (p≤0.05) are indicated in bold, except when the alpha level of ANOVA was above 0.05 (Continued)
EGFP-htau untreated DG B6 5 10 8±4.49 p = 0.933
EGFP-htau untreated DG APPSDL 7 17 8±2.73
Construct Condition Region Genotype Mice (n) Cells (n) Mean ± s.e.m
(based on cell
number)
One way ANOVA (together with
EGFP-htau untreated, both
genotypes, same region)
p values (B6 vs. APP) p values ( vs. untreated
EGFP-htau same region
and genotype)
EGFP-htau DAPT CA1 B6 4 6 36±2.11 F (3,24) = 4.920 ; p = 0.0084 p = 0.2443 P > 0.9999
EGFP-htau DAPT CA1 APPSDL 4 7 31±2.00 p = 0.0511
EGFP-htau DAPT CA3 B6 5 6 30±1.95 F (3,22) = 8.519 ; p = 0.0006 p = 0.1167 p = 0.0058
EGFP-htau DAPT CA3 APPSDL 4 8 25±1.51 p = 0.0076
EGFP-htau CPP CA1 B6 5 7 32±4.34 F (3,25) = 2.434 ; p = 0.0885 p = 0.4497 p = 0.4497
EGFP-htau CPP CA1 APPSDL 6 7 28±3.53 p = 0.3310
EGFP-htau CPP CA3 B6 6 6 32±2.77 F (3,23) = 5.381 ; p = 0.0059 p = 0.1041 p = 0.0509
EGFP-htau CPP CA3 APPSDL 7 9 26±2.19 p = 0.0339
EGFP-htau EpoD CA1 B6 7 8 27±1.83 F (3,27) = 4.824 ; p = 0.0081 p = 0.5753 p = 0.0203
EGFP-htau EpoD CA1 APPSDL 8 8 25±1.31 p = 0.5753
EGFP-htau EpoD CA3 B6 7 8 29±2.86 F (3,23) = 4.362 ; p = 0.0143 p = 0.4458 p = 0.0120
EGFP-htau EpoD CA3 APPSDL 7 7 26±2.93 p = 0.0668
EGFP-Ala htau untreated CA1 B6 5 7 26±3.41 F (3,24) = 3.655 ; p = 0.0266 p = 0.1135 p = 0.0430
EGFP-Ala htau untreated CA1 APPSDL 4 6 34±3.12 p = 0.0288
EGFP-Ala htau untreated CA3 B6 5 6 25±3.06 F (3,20) = 4.572 ; p = 0.0135 p = 0.5032 p = 0.0028
EGFP-Ala htau untreated CA3 APPSDL 4 6 28±3.72 p = 0.1878
EGFP-PHP htau untreated CA1 B6 4 7 32±3.28 F (3,24) = 3.736 ; p = 0.0246 p = 0.1469 p = 0.3815
EGFP-PHP htau untreated CA1 APPSDL 4 6 25±2.45 p = 0.6630
EGFP-PHP htau untreated CA3 B6 5 6 38±6.57 F (3,20) = 0.6744 ; p = 0.5778 p = 0.3253 p = 0.7762
EGFP-PHP htau untreated CA3 APPSDL 4 6 31±6.14 p = 0.6702
Construct Condition Region Genotype Mice (n) Cells (n) Mean ±
s.e.m (based
on cell number)
One way ANOVA (together with
EGFP untreated, both genotypes,
same region)
p values (B6 vs. APP) p values ( vs.
untreated EGFP
same region and
genotype)
EGFP CPP CA1 B6 6 7 34±3.15 F (3,23) = 0.3279 ; p = 0.8052 p = 0.7518 p = 0.6011
EGFP CPP CA1 APPSDL 6 6 36±2.74 p > 0.9999
EGFP CPP CA3 B6 5 5 33±3.24 F (3,22) = 2.872 ; p = 0.0594 p = 0.1730 p = 0.2132
EGFP CPP CA3 APPSDL 5 6 26±3.16 p = 0.1396
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Table 1 Dendritic simplification in an ex vivo model of Alzheimer’s disease. Summary representation of the effect of the expressed construct, the genotype of the mouse and
pharmacological treatments on total path length (A) and number of branching points (B). Statistical evaluation was performed using two-tailed, unpaired Student’s t test for
comparison of the two genotypes under control conditions (untreated), and one way ANOVA with post hoc Fisher’s LSD test for multiple comparisons of drug treatments or
different tau constructs. P values, which represent statistical significance (p≤0.05) are indicated in bold, except when the alpha level of ANOVA was above 0.05 (Continued)
EGFP EpoD CA1 B6 6 6 25±2.16 F (3,23) = 1.069 ; p = 0.3814 p = 0.3033 p = 0.2778
EGFP EpoD CA1 APPSDL 7 7 31±0.57 p = 0.4130
EGFP EpoD CA3 B6 6 6 23±3.24 F (3,23) = 4.970 ; p = 0.0084 p = 0.0141 p = 0.0010
EGFP EpoD CA3 APPSDL 6 6 35±1.99 p = 0.6501
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Golovyashkina et al. Molecular Neurodegeneration  (2015) 10:60 Page 13 of 17We have provided evidence that Aβ induces changes
in htau by acting on NMDARs, which then lead to local
modulation of microtubule dynamics (Fig. 7). This pro-
vokes the question, how the mechanisms of dendritic
simplification relate to the other facets of the neuro-
degenerative triad that occur during AD, i.e., to spine
changes and neuron loss. We and others have previ-
ously reported that soluble Aβ causes loss of spines
in an NMDAR-dependent manner, but independent of
tau [5, 26]. This contrasts with the requirement of
tau for the induction of dendritic simplification and
indicates that different mechanisms operate to medi-
ate spine alterations on the one hand, and changes of
dendritic arborization on the other. Neuron loss re-
quires a combined action of Aβ and tau [5, 41, 42],
indicating that dendritic simplification and loss of
neurons share the engagement of tau. However, tau-
dependent cell loss occurred in the CA3 region, but
not in CA1 neurons [21], whereas dendritic simplifi-
cation was mostly evident in CA1 and not in CA3.
The inverse regional relationship argues against the
hypothesis that dendritic simplification is a forerunner
to neuronal loss [9]. Furthermore, neuron loss was
blocked in the presence of phosphoblocking tau [5],
whereas the same construct induced dendritic simpli-
fication per se as shown in the present study. Thus
the data indicate that dendritic simplification isFig. 7 Schematic representation showing the proposed pathway
that mediates dendritic simplification. The formation of Aβ and
NMDAR activity are required for dendritic simplification since
blocking of Aβ production or inhibition of NMDAR activity
abolish the pathology. NMDAR activation leads to pathologic
dephosphorylation of dendritic tau, which shows at physiological
conditions a higher phosphorylation state. Dephoshorylation
increases tau’s activity to stabilize dendritic microtubules, an
activity that is mimicked by the microtubule-stabilizing drug
EpoD or phosphoblocking tau (Ala htau). Continuous lines show
direct effects, and dashed lines show indirect effects with
potential intermediate stepsmechanistically distinct from the other two features
of the neurodegenerative triad.
Importantly, we demonstrated that dendritic simplifi-
cation was induced in a highly localized manner in the
hippocampus. In AD patients, major dendritic regression
of CA1 neurons was found [11], whereas no reduction
of dendritic extent in CA3 pyramidal neurons occurred
[12, 13]. Remarkably, the region-specificity was recapitu-
lated in our model suggesting that this model provides a
useful system to analyze the mechanism of region-
specific dendritic simplification. Since soluble Aβ is glo-
bally present, dendritic tau appears to play a decisive
role in mediating region specific effects, which might
differ between cells and subcellular microdomains. It has
previously been shown that tau is present to a major ex-
tent in dendrites where it generally has a higher phos-
phorylation state than in the axon [19, 43]. In this study
we have demonstrated that a phosphoblocking tau con-
struct leads to increased microtubule stabilization that
causes dendritic simplification suggesting that condi-
tions, which decrease the phosphorylation state of den-
dritic tau at certain sites can be harmful. None of the
tau constructs or treatment conditions changed the den-
dritic tau level suggesting that a redistribution of tau
does not play a role in mediating dendritic simplification
(Table 2). Using a cellular model system we showed in
this study that low nanomolar concentrations of secreted
Aβ cause a decreased phosphorylation at S262, a site
that, when phosphorylated, abolishes tau’s interaction
with microtubules [34].
Interestingly, phosphorylated S262 (but not T181 or
S214) is a preferential target for the major brain phos-
phatase calcineurin (PP2B) [44, 45], which has previ-
ously been shown to be activated by Aβ in a NMDAR-
dependent pathway [5, 26] and was reported to be in-
volved in dendritic simplification [8]. Our data could
suggest that phosphorylation at S262 might be a target
for a selective intervention in the mechanisms that lead
to dendritic simplification. Furthermore we have shown
that NMDAR activation is involved in inducing dendritic
simplification and that dendritic simplification takes
place at sites of Schaffer collateral inputs where postsyn-
aptic LTP occurs [46].
Conclusions
Using an ex vivo model we showed that (1) dendritic
simplification is induced by Aβ and mediated by tau
through NMDAR activation in a spatially highly re-
stricted manner; (2) dendritic simplification is mechan-
istically distinct from other neurodegenerative events;
and (3) dendritic simplification involves microtubule
stabilization by dendritic tau, which is dephosphorylated
at specific sites. The proposed pathway that mediates
dendritic simplification is shown in Fig. 7.
Table 2 Effect of drug treatment on dendritic tau levels. Dendritic tau levels in 2nd or 3rd order of CA1 neurons expressing the
respective construct were determined as described in “Methods”. For every neuron, 3–4 measurements were performed and
averaged. Statistical evaluation was performed using two-tailed, unpaired Student’s t test for untreated cultures, and one way
ANOVA with post hoc Fisher’s LSD test for multiple comparisons of drug treatments or different tau constructs. Note that alpha
levels of ANOVA did not reach significance (p≤0.05) for any condition
Construct Condition Region Genotype Mice
(n)
Cells
(n)
Mean ± s.e.m (based on
cell number) of normalized
intensity values
Student’s t test
p values (B6 vs. APP)
EGFP-htau untreated CA1 B6 3 5 1.061±0.099 p = 0.6210
EGFP-htau untreated CA1 APPSDL 5 5 1.111±0.120
Construct Condition Region Genotype Mice
(n)
Cells
(n)
Mean ± s.e.m (based on
cell number) of normalized
intensity values
One way ANOVA (together
with EGFP-htau untreated,
both genotypes)
p values
(B6 vs. APP)
p values (vs.
untreated
same genotype)
EGFP-htau DAPT CA1 B6 3 6 0.827±0.066 F (3,17) = 2.183 ; p =
0.1275
p = 0.0273 p = 0.2007
EGFP-htau DAPT CA1 APPSDL 4 5 1.197±0.154 p = 0.5981
EGFP-htau EpoD CA1 B6 4 5 1.119±0.138 F (3,16) = 0.2108 ; p =
0.8874
p = 0.8533 p = 0.5763
EGFP-htau EpoD CA1 APPSDL 5 5 1.148±0.066 p = 0.8135
EGFP-htau CPP CA1 B6 5 5 0.945±0.176 F (3,16) = 1.334 ; p =
0.2984
p = 0.3752 p = 0.6129
EGFP-htau CPP CA1 APPSDL 4 5 0.793±0.019 p = 0.0745
EGFP-Ala
htau
untreated CA1 B6 5 5 1.083±0.135 F (3,16) = 0.6240 ; p =
0.6098
p = 0.2952 p = 0.7390
EGFP-Ala
htau
untreated CA1 APPSDL 5 5 0.917±0.068 p = 0.2240
EGFP-PHP
htau
untreated CA1 B6 3 5 1.174±0.064 F (3,16) = 0.5229 ; p =
0.6727
p = 0.9881 p = 0.2937
EGFP-PHP
htau
untreated CA1 APPSDL 3 5 1.172±0.080 p = 0.6495
Golovyashkina et al. Molecular Neurodegeneration  (2015) 10:60 Page 14 of 17The finding that the mechanisms inducing and mediating
dendritic simplification are distinct from other AD related
abnormalities could be relevant for the development of
treatments to slow down the neurodegenerative triad and
should be taken into account when testing new approaches.
In particular, treatments leading to an overall decrease of
tau phosphorylation [47] might have a negative impact on
neuronal connectivity since they could induce dendritic
simplification.
Methods
Animals
Heterozygous APPSDL transgenic mice [48] expressing hu-
man APP695 with three familial AD mutations were used.
APPSDL mice express equimolar concentrations of Aβ40
and Aβ42 already at embryonal age [49]. Genotyping was
performed as described previously [5]. APPSDL transgenic
and C57BL/6 J (B6) control animals were maintained and
sacrificed according to National Institutes of Health
Guidelines and German Animal Care Regulations.
Materials
Chemicals were purchased from Sigma (Steinheim,
Germany), culture medium and supplements from Sigma
and Invitrogen (Darmstadt, Germany), culture dishes andplates from Nunc (Langenselbold, Germany), and mem-
brane culture inserts from Millipore (Billerica, MA,
USA). γ-secretase inhibitor N-[N-(3,5-difluorophenace-
tyl)-1-alanyl]-S-phenylglycine t-butyl ester (DAPT) was
purchased from Merck (Darmstadt, Germany). Epothilone
D (EpoD) was prepared as previously described [50, 51].
The spectroscopic properties of the compound were identi-
cal to those reported in the literature. Compound purity
was >95 % as determined by LC-MS and NMR analyses.
Sindbis virus constructs
Construction of virus was performed as described previ-
ously [21]. The following constructs were used for the
experiments: pSinRep5-EGFP, pSinRep5-EGFP-352wt
htau, pSinRep5-EGFP-352 Ala htau, pSinRep5-EGFP-
352 PHP htau. For Ala and PHP htau, respectively, 10
sites (Ser198, Ser199, Ser202, Thr231, Ser235, Ser396,
Ser404, Ser409, Ser413, and Ser422) were mutated to
alanine to block or to glutamate to mimic phosphoryl-
ation at the respective residues [31].
Organotypic hippocampal slice cultures and Sindbis virus
infection
Hippocampal slice cultures were prepared from mice of
either sex and processed as described previously [5, 52].
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Sindbis virus. For some experiments, slices were treated
with 0.5 μM DAPT, 20 μM 3-(2-carboxypiperazin-4-
yl)propyl-1-phosphonic acid (CPP), or 0.2 nM EpoD
starting on day 11 in vitro. Cultures were fixed at day 3
post infection. For preparation of lysates, cultured hip-
pocampal slices were visually inspected on day 15
in vitro. Slices with similar infection rates were lysed in
RIPA buffer as described previously [5].
Confocal microscopy, image processing and semi-
automated analysis of neuronal morphology
Confocal high-resolution microscopy of complete princi-
pal hippocampal neurons was performed as described
previously [22]. Each single neuron was imaged in 8 to
12 overlapping image stacks with voxel size of 0.14 ×
0.14 × 0.44 μm in x-y-z directions. 3D reconstruction of
whole neurons was performed using Neuromantic soft-
ware (University of Reading, Reading, UK) in semi-
automated mode.
For the determination of dendritic tau levels, non
overlapping basal dendritic segments of 2nd or 3rd order
of CA1 neurons expressing EGFP-tagged tau constructs
were selected. Image stacks between first and last ap-
pearance of the respective dendritic segment were pro-
jected onto a single layer and mean intensity values in
the middle of the process were determined and cor-
rected for the detector gain.
Culture of PC12 and HEK cells
PC12 cells stably transfected to express PAGFP-tagged
wt 352 htau were cultured in serum-DMEM in the pres-
ence of 250 μg/ml Geneticin as described previously
[53]. Cells were plated onto 10-cm collagen-coated TC-
plates at 2 × 104 cells/cm2. On the next day, medium
was replaced with low serum DMEM (DMEM with 1 %
(vol/vol) serum) containing 100 ng/ml 7S mouse NGF
(Alomone Laboratories). After 4 days, medium was
replaced with serum-free medium (NB/B-27, Thermo
Fisher Scientific) containing 100 ng/ml 7S mouse NGF and
supernatant of Aβ-producing HEK cells (HEK-SW) to yield
0.7 or 3.5 nM of Aβ. Same amounts of supernatant of
untransfected HEK cells (HEK-con) were added as control.
Cell lysates were prepared 24 h. later as described by [53].
HEK-SW cells (HEK 293-APPswe; [54]), which were
stably transfected with APP carrying the Swedish familial
AD mutation resulting in increased Aβ secretion, were
obtained from C. Haass (University of Munich) and cul-
tured in DMEM containing 10 % fetal calf serum. As a
control, HEK 293FT cells (Life Technologies) were used.
Cells were cultured until 60–70 % confluency, medium
was exchanged and the supernatant collected 24 h. later.
The supernatant was filtered (0.22 μm pore size) and shock
frozen in aliquots in liquid nitrogen. The concentration ofAβ1–40 and Aβ1–42 was determined by ELISAs according
to the manufacturer’s description (EZHS40, EZHS42;
Millipore). The ratio of Aβ1–42 to Aβ1–40 in the super-
natant of HEK-SW cells was 1:4.
Immunoblot analysis
Same volumes of lysates were subjected to SDS-
PAGE, transferred to Immobilon-P (Millipore) and
stained. Immunodetection used the following antibodies:
Phosphorylation-independent tau antibodies: HT7 (hu-
man tau, mouse; Pierce); phosphorylation-dependent tau
antibodies: AT270 (pThr181, mouse; Pierce), p214 (Ser-
214, rabbit; Biosource), pS262 (pSer262, rabbit; Bio-
source). Also used were anti-GFP (rabbit; Invitrogen),
anti-tubulin (mouse, DM1A), anti-acetylated tubulin
(mouse; 6-11B-1), and anti-actin (mouse, JLA20; Amer-
sham) antibodies. As secondary antibodies, peroxidase–
conjugated goat anti–mouse and anti–rabbit antibodies
(Jackson ImmunoResearch Laboratories, Inc.) were used.
Detection using enhanced chemiluminiscence and quan-
titation were performed as described previously [17].
Statistical analysis
Statistical evaluation was performed using one way ana-
lysis of variance (ANOVA) with post hoc Fisher's least
significant difference (LSD) test for multiple compari-
sons and two-tailed, unpaired Student’s t test for com-
parison of the two genotypes at control conditions. For
the tau phosphorylation experiments, one-sample
Student’s t test was performed. Data are shown as mean
and s.e.m. Sholl analysis [23] was performed separately
for basal and apical parts of dendritic trees.
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